| NanoBiotech Reviews 2006-03-31, 5:26 pm |
| World J Urol. 2006 Feb;24(1):51-4. Epub 2006 Jan 10. Related Articles,
Links
The role of nanobacteria in urologic disease.
Wood HM, Shoskes DA.
Glickman Urological Institute, Cleveland Clinic Foundation Cleveland,
Mail Code: A100 OH, 9500 Euclid Avenue, Cleveland, OH 44195, USA,
dshoskes@mac.com.
Recent data proposing an extremely small, self-replicating agent termed
"nanobacteria" has raised a great deal of controversy within the
scientific community. Since these agents have been isolated within the
genitourinary tract, much research has focused attention on the
potential role these particles may play in the development of urologic
pathology, including polycystic kidney disease, renal calculi, and
chronic prostatitis. Recent clinical research targeting these agents
has proven effective in treating some patients with refractory category
III prostatitis (chronic pelvic pain syndrome). This article reviews
the current state of nanobacteria research and explore where these
particles may impact urologic disease.
PMID: 16402263 [PubMed - in process]
|